Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: Results of a randomized trial

Metabolism: Clinical and Experimental

Volumn 63, Issue 10, 2014, Pages 1296-1303

  Stein, Peter ^a   Berg, Jolene K ^b   Morrow, Linda ^c   Polidori, David ^d   Artis, Eunice ^a   Rusch, Sarah ^d   Vaccaro, Nicole ^d   Devineni, Damayanthi ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Davita Clinical Research Casa Davita   (United States)

^c Profil Institute for Clinical Research Inc   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Mixed meal tolerance test; Postprandial glucose excursion; Urinary glucose excretion

Indexed keywords

C PEPTIDE; CANAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; THIOPHENE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; URINALYSIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; KIDNEY; METABOLISM; MIDDLE AGED; MIXED-MEAL TOLERANCE TEST; POSTPRANDIAL GLUCOSE EXCURSION; URINARY GLUCOSE EXCRETION;

MIXED-MEAL TOLERANCE TEST; POSTPRANDIAL GLUCOSE EXCURSION; URINARY GLUCOSE EXCRETION;

BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; GLUCOSE; GLUCOSIDES; HUMANS; KIDNEY; MALE; METFORMIN; MIDDLE AGED; POSTPRANDIAL PERIOD; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84908259812     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.07.003     Document Type: Article

References (16)

1. B. Bode, K. Stenlöf, and D. Sullivan Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial Hosp Pract 41 2 2013 72 84
2. W.T. Cefalu, L.A. Leiter, and K.-H. Yoon Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 382 9896 2013 941 950
3. F.J. Lavalle-González, A. Januszewicz, and J. Davidson Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 56 12 2013 2582 2592
4. J. Rosenstock, N. Aggarwal, and D. Polidori Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 6 2012 1232 1238
5. G. Schernthaner, J.L. Gross, and J. Rosenstock Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial Diabetes Care 36 9 2013 2508 2515
6. K. Stenlöf, W.T. Cefalu, and K.-A. Kim Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 15 4 2013 372 382
7. J.P. Wilding, G. Charpentier, and P. Hollander Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 67 12 2013 1267 1282
8. J.F. Yale, G. Bakris, and B. Cariou Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 15 5 2013 463 473
9. S. Sha, D. Devineni, and A. Ghosh Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects Diabetes Obes Metab 13 7 2011 669 672
10. Y. Liang, K. Arakawa, and K. Ueta Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models PLoS ONE 7 2 2012 e30555
11. V. Gorboulev, A. Schurmann, and V. Vallon Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion Diabetes 61 1 2012 187 196
12. D. Polidori, S. Sha, and S. Mudaliar Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study Diabetes Care 36 8 2013 2154 2161
13. D. Devineni, L. Morrow, and M. Hompesch Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin Diabetes Obes Metab 14 6 2012 539 545
14. D. Polidori, S. Sha, and T. Heise Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics Clin Pharmacol Drug Dev 2014 10.1002/cpdd.115
15. E. Ferrannini, E. Muscelli, S. Frascerra, S. Baldi, A. Mari, and T. Heise Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J Clin Invest 124 2 2014 499 508
16. A. Merovci, C. Solis-Herrera, G. Daniele, R. Eldor, T.V. Fiorentino, and D. Tripathy Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production J Clin Invest 124 2 2014 509 514